U.S. Peripheral CTO Device Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMMD2099 | Last Updated On: Jun 21 2022 | Available Formats

> U.S. Peripheral CTO Device Market Expected to reach at a high CAGR by 2029: DataM Intelligence

U.S. Peripheral CTO Device Market is segmented By Device type (Crossing CTO device, TruePath, Viance Device, Re-entry device, CenterCross CTO device, Prodigy, and CrossLock, Others), By End-user (Hospitals, Ambulatory surgical centers, Others), and By Region – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Market Overview

The " U.S. Peripheral CTO Device Market" is expected to grow at a high CAGR during the forecasting period (2022-2029).

Chronic total occlusions (CTOs) are a challenging lesion subset in the peripheral circulation. CTOs, particularly long or heavily calcified, have been the domain of surgeons for distal bypass. Although surgery is still an option in some patients, the explosion of crossing technologies and atherectomy devices has allowed several endovascular specialists to tackle these lesions with a greater success rate.

Market Dynamics

The major driving forces are the increasing number of regulatory approvals and the increasing number of pipeline products.

The increasing number of regulatory approvals is expected to boost the market. For instance, in January 2019, XableCath, Inc. has received the U.S. Food and Drug Administration (FDA) approval for Peripheral Crossing Catheters, XableCath blunt and abrasion tip catheters. Also, in April 2018, Asahi Intecc Co., Ltd. have received US Food and Drug Administration approval for a chronic total occlusion (CTO) Corsair and Corsair Pro microcatheters and its coronary guidewires that include the MiracleBros series, Confianza series, Fielder series, and Gaia series, in the United States. Thus, the increasing number of regulatory approvals is driving the market.

The increasing number of pipeline products is expected to boost the market. For instance, in April 2018, Asahi Intecc Co., Ltd. have received US Food and Drug Administration approval for chronic total occlusion (CTO) indication for its Corsair and Corsair Pro microcatheters and its coronary guidewires that include the MiracleBros series, Confianza series, Fielder series, and Gaia series. It is the first expanded indication for Asahi devices in the United States. In March 2018, Reflow Medical started a clinical study of its Reflow Wingman catheters, exploring the device’s ability to cross chronic total occlusions in peripheral lesions. The ability to cross CTOs is directly related to acute procedural success and favorable long-term outcomes, including preventing the need for either bypass surgery or amputation. Thus, the increasing number of pipeline products is driving the market.

However, the increasing number of substitute products is restraining the growth of the market. For instance, in August 2018, Eximo Medical Ltd. has received 510(k) clearance from the U. S. Food & Drug Administration (FDA) for its B-Laser Atherectomy System for Peripheral Artery Disease (PAD). B-Laser is a transformative 355nm wavelength laser technology designed to address unmet clinical needs for treating multiple vascular indications. In June 2018, Medtronic plc received U.S. Food and Drug Administration (FDA) approval for 200mm and 250mm lengths.PACT Admiral Drug-Coated Balloon (DCB) to treat long superficial femoral artery (SFA) lesions in patients with peripheral artery disease (PAD).

Market Segmentation

The U.S. peripheral CTO device market can be segmented by device type into crossing CTO device, TruePath, Viance Device, Re-entry device, CenterCross CTO device, Prodigy and CrossLock and others.

The crossing CTO device segment is expected to grow at a high rate over the forecast period. A Crossing CTO device is a unique system designed to achieve intraluminal penetration over long occlusions. It is approved for coronary and peripheral applications. The generator is controlled with a footswitch with a high-frequency transducer and the Crosser catheter. The increasing number of clinical studies on crossing CTO devices is one of the key factors fueling the U.S peripheral CTO device market growth. For instance, in March 2018, Reflow Medical has started a clinical study of its Reflow Wingman catheters, exploring the device’s ability to cross chronic total occlusions in peripheral lesions. In November 2017, SoundBite Medical Solutions, Inc., have started a clinical study on SoundBite Crossing System – Peripheral. Thus, the increasing number of clinical trials on crossing CTO devices is driving the market.

The Re-entry device segment is expected to grow at a high rate over the forecast period. This is owing to the presence of key players manufacturing the Re-entry devices. For instance, Cordis Corporation has introduced the Outback Elite re-entry catheter in the United States. The new product in the Cordis portfolio to treat patients with chronic total occlusions (CTOs) in peripheral artery disease adds to a suite of specialty and workhorse solutions designed to support physicians in crossing the most complex lesions. Thus, the presence of key players manufacturing the re-entry devices is driving the market.

The U.S. peripheral CTO device market can be segmented by end-user into hospitals, ambulatory surgical centers, etc.

Hospitals account for a major share of the U.S. peripheral CTO devices market due to better accessibility to CTO devices during chronic total occlusion. Hospitals procure medical products, accessories, and consumables in a bulk quantity and engage closely with suppliers and manufacturers, reimbursement authorities, and government agencies.

Competitive Landscape

The major players operating in the U.S. peripheral CTO devices market are Medtronic, Boston Scientific Corporation, Avinger, Inc., Cardinal Health, Koninklijke Philips N.V., Cook Medical Incorporated, C.R. Bard, Baylis Medical Company, BTG Vascular, and Soundbite Medical Solutions.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the U.S. peripheral CTO devices market. For instance,

On December 18, 2018, Soundbite Medical Solutions received a CE mark for SoundBite™ Crossing System Peripheral Gen 2, an improved version of its shockwave-based technology platform intended to treat peripheral Chronic Total Occlusions (CTOs).

On June 12, 2018, SoundBite Medical Solutions Inc. (SBMS) received a $ 5.2 million second and final tranche of Series A financing, bringing the total proceeds raised in the Series A financing to $25 million.

In June 2017, Philips relaunched the Pioneer Plus catheter, the only re-entry device with intravascular ultrasound guidance.

Why Purchase the Report?

  • Visualize the composition of the U.S. Peripheral CTO Device market across each device type and end-user, highlighting the key commercial assets and players.
  • Identify commercial opportunities in the U.S. Peripheral CTO Device market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the U.S. Peripheral CTO Device market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Type mapping in excel for the key Services of all major market players.

The U.S. Peripheral CTO Device Market report would provide access to an approx, 36 market data tables, 25 figures, and 220 pages.

Target Audience:

  • Equipment Suppliers/ Buyers
  • Type Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Trending Topics

Peripheral Nerve Stimulators Market

Peripheral Neuropathy Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Discount Applied



25% discount offer

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest